Thursday, January 10, 2013

BREAKING: FDA Advisory Committee Vote: Invokana Should Be Approved

Not terribly surprising -- and we still need to wait for a full commission vote, but in as few as six weeks' time, Januvia should prepare to compete head to head with Invokana.

The FDA Advisory Panel just voted, 10-5, to recommend that FDA approve this new drug candidate for adults with Type-2 diabetes.

Beware what that portends for Januvia -- and Whitehouse Station. This is now Merck's biggest selling franchise.

No comments: